Filing Details
- Accession Number:
- 0001567619-20-020222
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-23 16:59:52
- Reporting Period:
- 2020-11-23
- Accepted Time:
- 2020-11-23 16:59:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1750284 | Olema Pharmaceuticals Inc. | OLMA | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1583977 | Cormorant Asset Management, Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | No | Yes | |
1599214 | Bihua Chen | C/O Cormorant Asset Management, Llc 200 Clarendon Street, 52Nd Floor Boston MA 02116 | Yes | No | Yes | No | |
1618442 | Cormorant Global Healthcare Master Fund, Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | Yes | No | |
1747677 | Cormorant Private Healthcare Fund Ii, Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | Yes | No | |
1817320 | Cormorant Private Healthcare Fund Iii Lp | 200 Clarendon Street, 52Nd Floor Boston MA 02116 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-11-23 | 2,845,544 | $0.00 | 2,845,544 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2020-11-23 | 425,000 | $19.00 | 3,270,544 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Convertible Preferred Stock | Disposition | 2020-11-23 | 2,122,367 | $0.00 | 2,122,367 | $0.00 |
Common Stock | Series C Convertible Preferred Stock | Disposition | 2020-11-23 | 723,177 | $0.00 | 723,177 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
- Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- Represents (i) 538,464 shares of Common Stock held by the Master Fund, (ii) 1,684,920 shares of Common Stock held by Fund II, (iii) 587,871 shares of Common Stock held by Fund III, and (iv) 34,289 shares of Common Stock held by the Account.
- Shares reported herein as purchased on November 23, 2020 represent (i) 404,940 shares purchased by the Master Fund, and (ii) 20,060 shares purchased by the Account.
- The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 412,342 shares held by the Master Fund, (ii) 1,684,920 shares held by Fund II, and (iii) 25,105 shares held by the Account.
- The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 126,122 shares held by the Master Fund, (ii) 587,871 shares held by Fund III, and (iii) 9,184 shares held by the Account.